Full Press Release Details
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of May 2017
Commission File Number: 001-36697
DBV TECHNOLOGIES S.A.
(Translation of registrant s name into English)
177-181 avenue Pierre Brossolette
92120 Montrouge France
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
| Exhibit | Description | |
| 99.1 | Press Release dated May 24, 2017. |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
| DBV TECHNOLOGIES S.A. | ||||||
| Date: May 24, 2017 | By: | /s/ David Schilansky | ||||
| Name | David Schilansky | |||||
| Title: | Chief Operating Officer |
AMF REGULATED INFORMATION
Montrouge, France, May 24, 2017
Extraordinary General Meeting of June 15, 2017
Procedures for Obtaining Preparatory Documents for the General Meeting
DBV Technologies (Euronext: DBV ISIN: FR0010417345 NASDAQ: DBVT) announced today that it will hold its Ordinary and Extraordinary General
Meeting on June 15, 2017 at 8:30 a.m. CEST at the Company s headquarters located at 177-181 Avenue Pierre Brossolette 92120 Montrouge, France.
The notice (l avis pr alable) containing the detailed agenda, draft resolutions as well as instructions to participate and vote for this
meeting was published in the French official legal announcement publication Direction de l Information L gale et Administrative (DILA), Bulletin des Annonces L gales Obligatoires (BALO) dated
May 10, 2017. The convening notice for shareholders (l avis de convocation) stating the time and place of the meeting will be published in the BALO dated May 31, 2017 and in the Legal Gazette on May 31, 2017.
The preparatory documents for the General Meeting listed in article R.
225-73-1 of the French Commercial Code are posted on the Investor Relations section of the Company s website located at:
The documents for the General Meeting will also be made available to
shareholders as of the date of the convening notice is issued. Thus, in accordance with applicable law and regulations:
About DBV Technologies
DBV Technologies is developing Viaskin , a proprietary technology platform with broad potential
applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT , DBV s method of delivering biologically active compounds to the immune system through intact skin.
With this new class of self-administered
and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved
treatments. DBV s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN
code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For
more information on DBV Technologies, please visit our website: www.dbv-technologies.com
Technologies Contact
Andrea Fassacesia, Weber Shandwick
Media Contact Europe
Caroline Carmagnol, Alize RP, Relations Presse